DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Recombinant factor VIIa
Recombinant factor VIIa
The Potential Role of Recombinant Activated FVII in the Management of Critical Hemato-Oncological Bleeding: a Systematic Review
Multiple Technology Appraisal Avatrombopag and Lusutrombopag
WO 2014/153004 Al 25 September 2014 (25.09.2014) P O P C T
Beverly, A., Ong, G., Wilkinson, KL, Doree, C., Welton, NJ, & Estcourt, LJ
Role, Laboratory Assessment and Clinical Relevance of Fibrin, Factor XIII and Endogenous Fibrinolysis in Arterial and Venous Thrombosis
HTRS 2021 Scientific Symposium PRELIMINARY VIRTUAL MEETING AGENDA
Current and Future Alternatives for Allogeneic Blood Product Transfusions
Package Insert
Integrating New Treatment Options Into the Management of Adult
Long-Term Management of Chronic Immune Thrombocytopenic Purpura in Adults
WFH Treatment Guidelines 3Ed Chapter 3 Laboratory
Treatment of Coagulopathy Related to Hepatic Insufficiency
Novothirteen® 2500 IU Catridecacog (Rys) Recombinant Coagulation Factor XIII
Illuminating the Role of Shared Decision-Making As the Hemophilia a Management Landscape Continues to Evolve: Progress in Practice
The Reversal Effect of Prothrombin Complex Concentrate (PCC)
Essential List of Medicinal Products for Rare Diseases: Recommendations from the Irdirc Rare Disease Treatment Access Working Group William A
Recombinant Factor Viia and Tranexamic Acid in Subgaleal Hemorrhage Sumesh Thomas1*, Arun Sundaram2, Nadira Rashid2 and Macgregor Steel3
Transfusion Replacement Strategies in Jehovah's Witnesses and Others Who Decline Blood Products
Top View
(12) United States Patent (10) Patent No.: US 8,987,339 B2 Askari Et Al
Comparative Effectiveness of In-Hospital Use of Recombinant
Coagulation Factor Products
PPH 2Nd Edn #23.Vp
Rapid Reversal of Warfarin-Associated Hemorrhage in the Emergency Department by Prothrombin Complex Concentrates
Coagulopathy in Liver Disease: a Balancing Act
Thrombocytopenia and Hemostatic Changes in Acute and Chronic Liver Disease: Pathophysiology, Clinical and Laboratory Features, and Management
Prevention of Spontaneous Bleeding in Dogs with Haemophilia a and Haemophilia B
Scientific Programme Sunday, 12. July 2020 Plenary Session State-Of-The-Art on Hemophilia and Rare Bleeding Disorders State-Of-T
Plasma Derived Versus Biotechnological Manufactured Medicine
Sept-Oct 2018 Monitoring International Trends (Pdf)
October 2017 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
Novoseven Coagulation Factor Viia (Recombinant)
The Early Use of Fibrinogen, Prothrombin Complex Concentrate
Scientific Programme Tuesday, 17. July 2018 Registration
Gene Therapy for the Hemophilias
Platelet Refractoriness
Use of Recombinant Factor VII in Cardiac Surgery